IsoPlexis — Merger or Acquisition (February 2023)
6 slides from IsoPlexis's merger presentation, Feb 8, 2023
Slide 1: BLI Leadership Team With Deep Life Science Experience
BLI Leadership Team With Deep Life Science Experience Winning culture — | #2 Customer Centricity — | <o: Continuing Innovation Commitment to Excellence in Quality | ——— Siddhartha Kadia, Ph.D. Chief Executive Officer Eric Hobbs, Ph.D. President, Global Operations Integration Planning Lead oe | ee Me
Slide 2: Integration Planning for PhenomeX
INTEGRATION PLANNING FOR PhenomexX A PREMIER FUNCTIONAL CELL BIOLOGY COMPANY
Slide 3: Three- to five-year strategic operating plan
Three- to five-year strategic operating plan 1 2 3 4 5 with a proven track on that will accelerate record in profitably through increased through a new sales profitable growth and scaling life sciences focus and rigor on structure, enhanced by early 2025 leverage our current tools and services devel
Slide 4: Timeline
Timeline Deal Signing we here. Day 1 — Integration Planning Financials SEC Review Shareholder Vote
Slide 5: The blueprint for PhenomeX
The blueprint for Phenome> ¢ Building a world-class team with focus on PhenomeX commercial channel ¢ Innovation engine to create the best product pipeline ¢ Path to ~$300M in revenue by 2027 ¢ Cashflow positive by Q4 2024 ¢ Build commercial channel to achieve $150M in run-rate revenue by Q4 2024 ¢ O
Slide 6: Forward-Looking Statements
Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products a